This inventor holds 1 USPTO granted patent. Top assignee: Johns Hopkins University. Active years: 2014.
Company Filing History:
Years Active: 2014
Title: Ravit Arav-Boger: Innovator in Anti-Cytomegalovirus Research
Introduction
Ravit Arav-Boger is a prominent inventor based in Baltimore, MD (US). She has made significant contributions to the field of virology, particularly in the development of therapeutic agents against cytomegalovirus (CMV) infections. Her innovative work has the potential to impact the treatment of CMV in humans.
Latest Patents
Ravit Arav-Boger holds a patent for her research titled "Anti-cytomegalovirus activity of artemisinin-derived dimers." This patent highlights the effectiveness of artemisinin-derived monomers and dimers in exhibiting in-vitro anti-CMV activity. The findings indicate that artemisinin dimers effectively inhibited CMV replication in human foreskin fibroblasts and human embryonic lung fibroblasts without causing cytotoxicity at the concentrations required for complete CMV inhibition. This research suggests that artemisinin dimers could serve as potent and non-cytotoxic inhibitors of CMV replication, indicating their potential use as therapeutic agents for treating CMV infections in humans.
Career Highlights
Ravit Arav-Boger is affiliated with Johns Hopkins University, where she continues her research and development efforts. Her work has garnered attention for its innovative approach to combating viral infections, particularly CMV, which poses significant health risks.
Collaborations
Ravit collaborates with Gary H Posner, who is also involved in research related to her work. Their partnership enhances the depth and breadth of their research initiatives.
Conclusion
Ravit Arav-Boger's contributions to the field of anti-CMV research exemplify the impact of innovative thinking in medicine. Her patent on artemisinin-derived compounds showcases the potential for new therapeutic options in treating viral infections.